Kroin David's Form 4 filing
Attovia Therapeutics, Inc. (ATTO) · filed Aug 10, 2026
- Accession no.
- 0001193125-26-342487
- Filed
- Aug 10, 2026, 4:30 PM ET
- Trade date
- Aug 6, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kroin DavidCIK 0001397513 | 10% Owner |
| Deep Track Capital, LPCIK 0001856083 | 10% Owner |
| Deep Track Biotechnology Master Fund, Ltd.CIK 0002015536 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Common Stock | CConversionAcquired | +1,957,138 | –F1 | – | 1,957,138 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Common Stock | CConversionDisposed | −1,957,138 | $0.00 | $0 | – | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I.